New York, March 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Dermatitis Global Market Report 2022" - https://www.reportlinker.com/p06245012/?utm_source=GNW
(Republic of Ireland) and Bristol-Myers Squibb.
The global dermatitis market is expected to grow from $5.92 billion in 2021 to $6.37 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.06 billion in 2026 at a CAGR of 6.1%.
The dermatitis market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex.
The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators and interleukin inhibitors.Corticosteroids are a group of steroid hormones generated by vertebrates’ adrenal cortex, and also synthetic equivalents of these hormones.
The different routes of administrations include topical, oral, injectable and is used in cancer, blood disorders, chronic diseases, infectious diseases. It is distributed through various channels such as hospital, retail pharmacies, drug stores, online or mail pharmacies
North America is the largest region in the dermatitis market in 2021.Middle East is expected to be the fastest growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Growth in atopic dermatitis market is primarily driven by the increasing global prevalence of the disease.Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults.
The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent.
The strict government regulations are one of the restraints for the dermatitis drug market.Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years).
In order to find the efficacy and efficiency of drug, it has to be tried on the every type of patients.The effects of certain drugs in adults are quite different than in children, as a reason result of the clinical trial cannot be used for the production of drug that will be served to the children.
This hinders the research and requires more efforts in clearing regulation set by FDA.For example, as the patient population is largely children, FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation.
The regulation is in compliance with Children’s Health Act of 2000 that requires all the children subjected to clinical trial be given additional protection.
The Dermatitis market has witnessed a trend of increasing Mergers and Acquisitions (M&As), done with the purpose of business expansion and increasing visibility.M&As are playing a significant role in today’s world and are assumed to expand this market in the years to come.
The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence.Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business.
For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also Biofrontera, Inc., a specialist in dermatology market acquired Cutanea Life Sciences, Inc.in 2019 for $7.3 million to increase their capital base and scale the business.
The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market.Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) that carry out quality checks before declaring the drugs suitable for consumption.
PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter.Similarly CDSCO is the central drug authority that is responsible for the approval of new drugs in India.
These tedious approval processes makes the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market.
The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
Read the full report: https://www.reportlinker.com/p06245012/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
